CytoDyn taps Vice President, Corporate Controller Antonio Migliarese as its new CFO

CytoDyn Inc (OTCQB:CYDY) has found its new CFO in-house, promoting Vice President, Corporate Controller, Antonio Migliarese, the company announced. 

Migliarese joined CytoDyn in January 2020, and he has held various senior financial leadership positions at both public and private companies since 2014, the company said. Prior to CytoDyn, his work included time as controller for Domaine Serene Winery and Vineyards Inc, corporate controller for Lightspeed Technologies Inc and CFO of Hollister & Blacksmith. 

All told, Migliarese has experience in strategic planning, financial planning, SEC reporting, internal controls, process improvement, IT, preparing companies to go public, treasury, debt, equity and M&A transactions, the company said. 

READ: CytoDyn to send topline results from severe coronavirus trial of leronlimab to regulators in India and the Philippines

“I am thrilled to continue to take on increased responsibilities and move into the role of CFO at CytoDyn,” Migliarese said in a statement. “I look forward to contributing to the CytoDyn executive team and continuing to create, drive and execute on the vision of CytoDyn’s financial organization, ensuring the company is properly equipped for its next phase of growth and successful in doing so.”

The former CFO, Michael Mulholland, will take on the role of senior vice president of finance and support CytoDyn in an advisory role, the company said.

“Unfortunately, for unexpected personal reasons I have had to make the difficult decision to assume a less demanding role to allow for more personal time for my family and myself,” Mulholland said. “I fully support Antonio’s appointment as the company’s next CFO, which is in line with the company’s succession plan. I am very proud of what our team has achieved over the past several years and am delighted to continue to support [CEO Nader Pourhassan] and Antonio…”

“Since joining CytoDyn, Antonio has made significant contributions to the company, taking on increasing scope and responsibilities and leading the charge of the financial organization as we transition from being a pre-revenue research and development-driven biotech company to a fully functional commercial organization,” Pourhassan said. 

“We are excited to have Antonio join our executive team. Michael Mulholland has helped prepare Antonio for this role and is equally pleased about this move. Under the financial leadership of Michael, CytoDyn successfully raised nearly half a billion dollars of capital propelling the company to where it is today. I am personally grateful for Michael and for his dedication, hard work and willingness to continue to support the company in his new role.”

CytoDyn Inc, a late-stage biotechnology company, is developing Vyrologix (leronlimab or PRO 140) to battle multiple diseases. Vyrologix has been granted Fast Track designation by the Food and Drug Administration for the treatment of HIV in combination with the cocktail known as highly active antiretroviral therapy (HAART) and for metastatic triple-negative breast cancer, which a rare variety of the condition that doesn’t respond to some treatments.

CytoDyn is also exploring Vyrologix’s use in the treatment of cancer, inflammatory conditions, autoimmune diseases and coronavirus (COVID-19).

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors